BFIC
CRSP icon

Bedell Frazier Investment Counselling’s CRISPR Therapeutics CRSP Stock Holding History

Bedell Frazier Investment Counselling’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,646
Closed -$372K – 132
2025
Q2 		$372K Sell
7,646
-7,118
-48% -$275K 0.09% 85
2025
Q1 		$502K Sell
14,764
-6,349
-30% -$269K 0.13% 70
2024
Q4 		$831K Sell
21,113
-5,244
-20% -$248K 0.21% 67
2024
Q3 		$1.24M Buy
26,357
+218
+0.8% +$11.1K 0.3% 59
2024
Q2 		$1.41M Buy
26,139
+2,192
+9% +$127K 0.34% 60
2024
Q1 		$1.63M Sell
23,947
-29
-0.1% -$2.08K 0.41% 55
2023
Q4 		$1.5M Sell
23,976
-611
-2% -$33.8K 0.41% 51
2023
Q3 		$1.12M Buy
24,587
+182
+0.7% +$9.4K 0.33% 52
2023
Q2 		$1.37M Sell
24,405
-2,698
-10% -$153K 0.4% 49
2023
Q1 		$1.23M Sell
27,103
-559
-2% -$27.1K 0.36% 48
2022
Q4 		$1.12M Sell
27,662
-3,805
-12% -$202K 0.29% 55
2022
Q3 		$2.06M Sell
31,467
-2,920
-8% -$212K 0.58% 41
2022
Q2 		$2.09M Buy
34,387
+4,282
+14% +$252K 0.64% 41
2022
Q1 		$1.89M Buy
30,105
+3,216
+12% +$202K 0.48% 47
2021
Q4 		$2.04M Buy
26,889
+1,742
+7% +$152K 0.5% 49
2021
Q3 		$2.81M Buy
25,147
+1,511
+6% +$190K 0.77% 43
2021
Q2 		$3.83M Buy
23,636
+694
+3% +$84.4K 0.97% 40
2021
Q1 		$2.79M Buy
22,942
+5,080
+28% +$767K 0.79% 42
2020
Q4 		$2.73M Buy
+17,862
New +$2.11M 0.84% 42

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bedell Frazier Investment Counselling's CRSP Position: Q3 2025 in Review

Bedell Frazier Investment Counselling sold out of CRISPR Therapeutics (CRSP) in Q3 2025, closing a stake of 7,646 shares — an estimated $372K sold.

Bedell Frazier Investment Counselling first reported a position in CRSP in Q4 2020 and held it in 19 quarters. The position peaked at $3.83M in Q2 2021. 440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

  • Bedell Frazier Investment Counselling reported no remaining CRISPR Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bedell Frazier Investment Counselling sold 7,646 CRISPR Therapeutics shares in Q3 2025, an estimated $372K.
  • Bedell Frazier Investment Counselling first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 19 quarters.
  • Bedell Frazier Investment Counselling's CRISPR Therapeutics position peaked at $3.83M in Q2 2021.
  • 440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on Bedell Frazier Investment Counselling's 13F filing for Q3 2025, filed 12 Nov 2025.